Luo Shangyi, Zhang Yajing, Jia Ying, Zhang Xue
NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, Harbin, China.
Heilongjiang Province Key Laboratory of Child Development and Genetic Research, Harbin Medical University, Harbin, China.
Neuropathol Appl Neurobiol. 2022 Oct;48(6):e12831. doi: 10.1111/nan.12831. Epub 2022 Jul 6.
Intratumoural heterogeneity (ITH) has been implicated in tumour growth and progression as well as therapy resistance. However, the extent of ITH of somatic copy number alterations (ITH-SCNAs) as a result of tumour evolution and its influence on clinical outcomes in diffuse glioma (DG) remain poorly understood.
We used an integrated computational method to infer clonal and subclonal SCNAs in 760 untreated primary DGs from The Cancer Genome Atlas. ITH-SCNAs at the genome-wide, peak (region with recurrent SCNAs) and gene level were calculated. We used the Kaplan-Meier estimators and Cox proportional hazards models to examine the associations of ITH-SCNA with patient outcomes. An independent cohort of 243 patients with paired initial and recurrent tumours from the Glioma Longitudinal Analysis Consortium was used for validation.
DGs showed widespread ITH-SCNA, with a median of 25.5% of SCNAs identified as subclonal. We found that clonal SCNA burden had stronger prognostic power than total SCNAs in IDH-mutant astrocytoma. Coamplifications of receptor tyrosine kinases (RTKs) tended to be subclonal, and subclonal RTK amplification was significantly associated with high tumour proliferative potential and unfavourable clinical outcomes in IDH-wild-type glioblastoma. In addition, we found that the prognostic values of the peak-level SCNAs were related to their mutated clonal architecture, from which three clonality-dependent prognostic patterns of SCNAs were proposed, including clonal-dominant, subclonal-dominant and clonality-independent schemas.
The systematic analysis of ITH-SCNAs in large cohorts of DGs highlighted the importance of considering the clonality of SCNA in discovery of tumour prognostic markers.
肿瘤内异质性(ITH)与肿瘤生长、进展以及治疗抵抗有关。然而,由于肿瘤进化导致的体细胞拷贝数改变的肿瘤内异质性(ITH-SCNAs)程度及其对弥漫性胶质瘤(DG)临床结局的影响仍知之甚少。
我们使用一种综合计算方法来推断来自癌症基因组图谱的760例未经治疗的原发性DG中的克隆性和亚克隆性SCNA。计算全基因组、峰值(具有复发性SCNA的区域)和基因水平的ITH-SCNA。我们使用Kaplan-Meier估计器和Cox比例风险模型来检验ITH-SCNA与患者结局的关联。来自胶质瘤纵向分析联盟的243例配对初始和复发性肿瘤患者的独立队列用于验证。
DG显示广泛的ITH-SCNA,其中位值为25.5%的SCNA被鉴定为亚克隆性。我们发现,在异柠檬酸脱氢酶(IDH)突变的星形细胞瘤中,克隆性SCNA负荷比总SCNA具有更强的预后能力。受体酪氨酸激酶(RTK)的共扩增倾向于亚克隆性,并且亚克隆性RTK扩增与IDH野生型胶质母细胞瘤的高肿瘤增殖潜能和不良临床结局显著相关。此外,我们发现峰值水平SCNA的预后价值与其突变的克隆结构有关,据此提出了三种依赖克隆性的SCNA预后模式,包括克隆主导型、亚克隆主导型和非克隆依赖型模式。
对大量DG队列中ITH-SCNA的系统分析强调了在发现肿瘤预后标志物时考虑SCNA克隆性的重要性。